Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "dosing"
Home
Hanmi Completes Key Phase 2 Dosing for Once-Weekly Rare Disease Drug Efpeglucagon
During normal digestion, dietary carbohydrates convert into glucose that circulates in the blood. Insulin functions like a key, unlocking muscle and...
09/12/2026, 04:20 ET
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C (compound name: OLX72021), an...
08/06/2026, 04:40 ET
MediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistem
South Korean biotechnology company MediPost has entered full-scale Phase 3 clinical testing in the United States for...
07/12/2026, 01:39 ET
When Supplements Turn Toxic: The Hidden Risks of Over-Dosing on Calcium and Vitamin D
While nutrients found in natural foods rarely cause significant side effects even when consumed in large amounts,...
03/09/2026, 08:10 ET
GC Cell Administers Experimental CAR-NK Therapy at Seoul National University Hospital Following MFDS Approval
GC Cell announced on Sept. 18 that South Korea’s Ministry of Food and Drug Safety has approved the compassionate use of...
09/27/2026, 10:22 ET
Yuhan Outlines Clinical Progress for Oral Targeted Anticancer Candidate YH42946 at WCLC 2026
Yuhan Corporation has detailed the status and trial design of the ongoing Phase 1/2 clinical study for YH42946, an oral...
09/23/2026, 22:29 ET
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4...
09/21/2026, 21:51 ET
Kyungdong Pharmaceutical and AUL Bio Seek Phase 1 Approval for Once-Monthly Obesity Drug AUL009
Kyungdong Pharmaceutical announced Sept. 2 that it has submitted an investigational new drug application to the...
09/13/2026, 09:58 ET
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...
09/03/2026, 05:34 ET
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
08/27/2026, 23:49 ET
1
2
3
Next